FRESENIUS SE+CO.KGAA/ DE0005785604 /
2024-04-19 5:32:34 PM | Chg. +0.20 | Volume | Bid5:32:34 PM | Ask5:32:34 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
26.86EUR | +0.75% | 92 Turnover: 2,442.70 |
-Bid Size: - | -Ask Size: - | 15.17 bill.EUR | - | - |
GlobeNewswire
2023-09-04
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
2023-08-31
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
GlobeNewswire
2022-02-25
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodia...
GlobeNewswire
2022-01-05
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
GlobeNewswire
2021-12-31
CIO Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its 15th Y...
GlobeNewswire
2021-12-09
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surge...
GlobeNewswire
2021-11-22
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
2021-11-22
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
2021-11-12
Humacyte Reports Third Quarter 2021 Financial Results and Provides Business Highlights
GlobeNewswire
2021-10-27
CIO Leadership: Exemplifying Authentic Leadership and Leveraging Personal Branding to Act as a Globa...
GlobeNewswire
2021-10-26
Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant P...